<DOC>
	<DOCNO>NCT02090608</DOCNO>
	<brief_summary>Proteinuria predominant risk factor renal disease progression Fabry disease ( FD ) . When urine protein excretion control &lt; 0.50 g/24 hr , rate loss glomerular filtration rate ( GFR ) significantly different 0 . However , enzyme replacement therapy ( ERT ) alone decrease proteinuria recommend patient receive ERT also receive anti Renin-Angiotensin-System ( RAS ) therapy . Emerging evidence show paricalcitol ( PCT ) reduce proteinuria presence intensify inhibition RAS ; however , evidence FD . The aim study evaluate antiproteinuric effect PCT FD patient proteinuria &gt; 0.50 g/24 hr persist despite ERT anti-RAS therapy titrate maximum tolerated dosage .</brief_summary>
	<brief_title>Paricalcitol Fabry Disease</brief_title>
	<detailed_description />
	<mesh_term>Proteinuria</mesh_term>
	<mesh_term>Fabry Disease</mesh_term>
	<mesh_term>Ergocalciferols</mesh_term>
	<criteria>genetically prove FD stable dose ERT least 12 month stable dose ACEi ARB titrate maximum tolerated dosage least 6 month persistent proteinuria &gt; 0.50 g/24 h despite use ERT ACEi/ARBs 2 consecutive sample within 12 week steroid/immunosuppressive treatment glomerular filtration rate change &gt; 30 % past 3 month PTH level &lt; 20 pg/mL serum phosphorus &gt; 5.0 mg/dL serum calcium ( adjust albumin ) &gt; 10.0 mg/dL active malignancy .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>January 2014</verification_date>
</DOC>